OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

OXB really got hammered today, didn't it? Let's hope the director buy will perk things up, though he's not exactly bought huge amounts.

I would say OXB is to AVOID as its outlook is not great...lacking in new products and this has been reflected in its chart. Trovax has also really taken a long long time to get approval and FDA might have more stringent rules.

Hlyeo98 you obviously know nothing about this company.It is in it's most exciting phase in it's history with potentially massive blockbusting products not far off, take a look at advfn.com to find out more from doctors and bioscience experts, Trovax alone could transform OXB share price into many pounds. Hlyeo this is a very dangerous time to be shorting this stock which i assume you are doing so take care. Also the graph has now shown a double bottom and the 6mth target would indicate 70p, a great opportunity to get in cheap or top up as has a director yesterday and myself

Nice summary robstuff.

70p??? Give me a break...or maybe you need spectacles. We will see who knows more. Time will tell. OXB will slide further downwards.

robstuff
I agree I have been topping up at these low prices; this will hit a 1+ in 2008

I must admit that I sold at 35p a few days ago, when Sellers seemed to vastly outnumber Buyers on Level2. However, I will be looking to buy more at some point - though I think it may yet slide further (contrary to what I thought last week - apologies!). Surely it will bounce back from 28.5p? Or will it slide further? - I've not kept up with the details of all the research so not sure of the various timelines now.

Buyers returning now, should be a great rebound..up 3p now. Don't blink on this share!!

Hi Robstuff, I kept my eye on OXB this morning and got back in at 31.00p. It did look as though it was on the turn, so hopefully it will be. I still think they'll do a deal eventually with a big pharmaco (probably Sanofi) but heaven knows when - would really kick myself if I were to miss it.

Very reassuring news out today - see the RNS. Commenting on the slide in share price and giving full update of various drug trials amd current cash position.

see what i mean, should rise back to 50 before xmas now

Moving now up 13%, about time.

OXFORD BIOMEDICA RESPONDS TO SHARE PRICE MOVEMENT AND REPORTS BUSINESS UPDATE

http://moneyam.uk-wire.com/cgi-bin/articles/200710250701003178G.html

Agreed, an excellent and timely RNS. Onwards & upwards from here.

RNS today explains about a patent dispute that OXB and Sigma-Aldrich are fighting in the US against Open Biosystems.

It seems they should win this: "In his order U.S. District Judge Charles A. Shaw concluded 'that the constructions of the disputed terms and phrases proposed by plaintiff are correct'."

However, it's always a distraction to a business and could keep the sp subdued for a while - that has tended to be the case with other pharmacos until the legal arguments are resolved.

You can read the full statement here:

http://www.londonstockexchange.com/LSECWS/IFSPages/MarketNewsPopup.aspx?id=1611227&source=RNS

OXB has got off to a good start at 34.0-35.5 so perhaps investors will see the positives in the statement?

UK smallcap opening - Oxford BioMedica firmer after favourable patent ruling - AFX

LONDON (Thomson Financial) - Shares in gene therapy company Oxford BioMedica ticked up a 1/4 penny to 33.5 in early deals after a favourable ruling in its patent dispute with Open Biosystems which confirms the strength and validity of certain intellectual property rights.

The ruling was part of the construction of patent claim terms in the patent infringement suit brought against Open Biosystems.

The lawsuit alleges that Open Biosystems infringes US Patent Nos. 6,924,123 and 7,056,699 entitled Lentiviral LTR Deleted Vector, which are owned by Oxford BioMedica and exclusively licensed to Sigma-Aldrich for research use, by selling, among other products, Open Biosystems' Lentiviral shRNAmir Library.

Good news Indeed! once you have a ruling that gives Oxb rights and more deals will follow if other Bios wish t use the science. Upwards from here, Oxbs share price is always late to respond I think due to the complex nature of the business - analysts need a bit of time before the institutions pile in.

Are you sure it is still upwards, Robstuff, or are you seeing an inverted graph?

hlyeo98
The graph does look a bit grap but OXB will recover.

these awful troughs have always been fantastic opportunities in the past - see the longer term graph at top of board. Always around this time of yr aswell. I'm still topping up at these prices